Finasteride Was Eaten by Pseudohermaphrodites?
doctor,
in this article back in 2005 you mention that the pseudohermaphrodites had a diet high in finasteride? I am kinda confused here. so pseudohermaphrodites ate finasteride due to them having low DHT?
I think you misread the post. A diet that was high in a finasteride-like substance caused pseudohermaphrodite characteristics in children of a mountain village in the Dominican Republic. These people did not know of finasteride. It was just a part of their diet. In the end, this was how finasteride was discovered. That is why finasteride is not to be taken by women who are pregnant and especially in the first trimester of pregnancy when the sex of the fetus establishes the gonads.
Please note the taking finasteride itself does NOT cause pseudohermaphrodites. These tidbits of information can sometimes be misconstrued into a wild tangent and taken out of context.
Doctor Rassman/PAK I hope you guys can read this reply and answer it.
Wasn’t finasteride created based on the research DR.julianne imperato-mcginley did in the dominican republic where she followed pseudohermaphrodites that had the alpha 5 reductase type 2 deficiency. I have not read anything regarding an aboriginal tribe in the Amazon. the research that I have read on the internet is that merck created finasteride based on DR.julianne imperato-mcginley research. it doesn’t say anything regarding aboriginal tribes in the Amazon
In 1974, Julianne Imperato-McGinley of Cornell Medical College in New York attended a conference on birth defects. She reported on a group of hermaphroditic children in the Caribbean who appeared sexually ambiguous at birth, and were initially raised as girls, but then grew external male genitalia and other masculine characteristic post-onset of puberty. Her research group found that these children shared a genetic mutation, causing deficiency of the 5α-reductase enzyme and male hormone dihydrotestosterone (DHT), which was found to have been the etiology behind abnormalities in male sexual development. Upon maturation, these individuals were observed to have smaller prostates which were underdeveloped, and were also observed to lack incidence of male pattern baldness.[47][48]
In 1975, copies of Imperato-McGinley’s presentation were seen by P. Roy Vagelos, who was then serving as Merck’s basic-research chief. He was intrigued by the notion that decreased levels of DHT led to the development of smaller prostates. Dr. Vagelos then sought to create a drug which could mimic the condition found in the pseudo-hermaphroditic children in order to treat older men who were suffering from benign prostatic hyperplasia.[49]
In 1992, finasteride (5 mg) was approved by the U.S. Food and Drug Administration (FDA) for treatment of benign prostatic hyperplasia (BPH), which Merck marketed under the brand name Proscar.
In 1997, Merck was successful in obtaining FDA approval for a second indication of finasteride (1 mg) for treatment of male pattern baldness (MPB), which was marketed under the brand name Propecia.